D-serine serum levels in patients with schizophrenia: Relation to psychopathology and comparison to healthy subjects

Jaromir Hons 1, Rastislav Zirko 1, Martina Ulrychova 2, Eva Cermakova 3, Jan Libiger 1

1. Department of Psychiatry, University Hospital Hradec Kralove and Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic.
2. Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic.
3. Department of Medical Biophysics, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic.

Correspondence to: Jaromir Hons, M.D.
Department of Psychiatry, University Hospital
Sokolska 581, Hradec Kralove 500 05, Czech Republic
PHONE: +420 495 832 228; FAX:+420 495 832 053
EMAIL: honsj@lfhk.cuni.cz

Submitted: 2008-04-03 Accepted: 2008-06-16 Published online: 2008-08-30

Key words: D-serine; negative symptoms; serine; NMDA receptor; excitatory amino acids; schizophrenia

Abstract

OBJECTIVES: The main objective was to test the hypothesis of the association between D-serine serum levels and negative symptoms in patients with schizophrenia. Secondary objective was to examine the assumption of D-serine serum levels difference between a population of mostly chronic patients with schizophrenia and healthy controls.

METHODS: We recruited outpatients with schizophrenia and age and gender matched healthy controls for the study. D-serine and total serine serum levels were measured by high-performance liquid chromatography (HPLC). The Positive and Negative Syndrome Scale (PANSS) and The Scale for the Assessment of Negative Symptoms (SANS) were used to assess schizophrenic symptoms. Non-parametric statistics was used to test the differences in D-serine and total serine serum levels and rank correlation was used to detect the associations with psychopathology.

RESULTS: We did not find any differences between patients (n=50) and controls (n=50) in D-serine serum levels. Patients had significantly lower total serine serum levels and higher D-serine/total serine ratio. D-serine serum levels were not associated with the PANSS or the SANS total and subscales scores. Total serine serum levels inversely correlated with the SANS total and the PANSS negative symptom subscale scores.

CONCLUSION: Decreased, not increased, serum levels of total serine negatively associated with intensity of negative symptoms were detected in patients with schizophrenia. We did not find any relationship between D-serine serum levels and negative symptoms among the patients. These findings do not agree with the previous reports of decreased D-serine and increased total serine serum levels in schizophrenia.
INTRODUCTION

Recently, there has been an accumulating evidence on the links between N-methyl-D-aspartate (NMDA) receptor dysfunction and pathogenesis of schizophrenia (Krystal et al. 2002; Moghaddam & Jackson, 2003). The interest in the role of NMDA receptor dysfunction in schizophrenia is primarily supported by the psychotomimetic action of the NMDA receptor antagonists (Luby et al. 1959; Javitt & Zukin, 1991; Krystal et al. 1994; Lahti et al. 1995) and the results of adjuvant treatment trials with the NMDA receptor modulators D-cycloserine (Goff et al. 1995; Goff et al. 1996; Goff et al. 1999; Heresco-Levy et al. 1998; Heresco-Levy et al. 2002; Evins et al. 2002), glycine (Javitt et al. 1994; Heresco-Levy et al. 1996; Heresco-Levy et al. 1999; Javitt et al. 2001; Heresco-Levy et al. 2004) and D-serine (Tsai et al. 1998; Heresco-Levy et al. 2005). The competitive NMDA receptor agonists, phencyclidine and ketamine, were consistently reported to induce psychopathology similar to schizophrenia in animal models (Noda et al. 2000; Becker et al. 2003; Wass et al. 2006; Nabeshima et al. 2006; Murai et al. 2007) and in human subjects including cognitive and negative symptoms (Javitt & Zukin, 1991; Krystal et al. 1994; Malhotra et al. 1996; Micalef et al. 2003; Krystal et al. 2005).

Excitatory amino acids like glycine and D-serine were used as adjunctive treatment to enhance glutamatergic neurotransmission in the treatment of schizophrenic symptoms. However, the systematic review and meta-analysis of clinical effects of the NMDA receptor agonists evaluated in 18 short-time trials provided inconsistent results: D-cycloserine (the NMDA receptor partial agonist) did not appear effective, glycine and D-serine (the NMDA receptor co-agonists) improved negative symptoms, but had no effects on positive symptoms and cognitive deficit (Tuominen et al. 2005).

Augmentation by D-serine improved negative, positive, cognitive (Tsai et al. 1998; Heresco-Levy et al. 2005) and depressive symptoms (Heresco-Levy et al. 2005) in patients treated with second generation antipsychotics. In contrast, studies with clozapine (Tsai et al. 1999) and risperidone (Lane et al. 2005) did not detect any treatment effect of augmentation by D-serine. This has been tentatively explained by the partially agonistic effect of these antipsychotics at the NMDA receptor.

Amino acid D-serine is an endogenous selective full co-agonist at the glycine modulatory site of the NMDA receptor and acts as a modulator of glutamatergic neurotransmission, neuronal migration and long term potentiation (LTP) (Scolari et al. 2007). D-serine levels in postmortem schizophrenic brains did not differ from healthy controls in prefrontal and parietal cortex and the regional distribution of free D-serine was associated with the distribution of the NMDA receptors (Kumashiro et al. 1995). Contrary to post-mortem studies, increased total serine and L-serine levels and decreased D-serine levels were found in the blood serum of patients with schizophrenia in comparison to healthy controls (Hashimoto et al. 2003; Yamada et al. 2005). Bendikov et al. (2007) detected decreased D-serine levels and D/L-serine ratio in cerebrospinal fluid (CSF) of patients with schizophrenia. The low ratio of D-serine to total serine was also found in CSF of drug-naive first episode patients with schizophrenia (Hashimoto et al. 2005).

The objective of this study was to test the hypothesis that low D-serine serum concentrations in patients with schizophrenia are associated with negative symptoms. We also compared D-serine serum levels in mostly chronic patients with schizophrenia to the serum levels in healthy controls to confirm the findings of low D-serine serum concentration in schizophrenia.

SUBJECTS AND METHODS

Study population

We recruited fifty patients with schizophrenia (33 males and 17 females) and fifty individually age and sex matched healthy subjects as controls into the study. Patients with schizophrenia were recruited at the Outpatient clinic of the Department of Psychiatry, University Hospital Hradec Kralove, Czech Republic. They were 18 years or older and had no history of substance abuse or positive urine toxicology prior to screening, no electroconvulsive therapy within the last 5 months and no pregnancy. They were diagnosed by two experienced psychiatrists in agreement with the ICD-10 Diagnostic Criteria for Research. Paranoid type of schizophrenia was the most frequent diagnosis (n=35), the other types were residual (n=7), undifferentiated (n=5), hebephrenic (n=2) and simple (n=1). The medical history of neurological disorders, cardiovascular disorders or renal dysfunction reported by patients or documented in their records led to exclusion from the study population. The patients were physically healthy upon examination and their laboratory assessments were within physiological limits. The baseline characteristics of patients are in Table 1. All patients, with a single exception, were treated with antipsychotic medication. The patient who was drug-naive had 2 years duration of psychosis and she was clinically stable. The antipsychotic medication that the patients used at the time of the assessments is in Table 1. Healthy controls had no history of psychiatric or neurological disorders or renal dysfunction and were free of any psychotropic medication.

Determination of D-serine and total serine

After 12 hours of overnight fasting, the blood samples for the determination of D-serine and total serine (D- and L-serine) serum levels were obtained by venipuncture from both, patients and healthy controls. The blood samples were collected between 8.00 and 9.30 a.m. (before breakfast) from all participants (in order to avoid the bias by different D-serine content in food).
Sample preparation: Venous blood was collected in Serum-SST™ II Advance tubes (BD Diagnostics, GB) and transported to the laboratory within one hour after collection. The serum was centrifuged and deproteinated by ultrafiltration in Microcon columns (Millipore, USA). We used D-norvaline as internal standard. Clear filtrate was stored at −20°C until analysis. Derivatization: The derivatization reagent contained 50 mg OPA (o-phthalaldehyde) in 5 ml methanol, 10 ml 0.2 mol/l boric acid in 0.2 mol/l KCl (potassium chloride), 10 ml 0.2 mol/l NaOH (sodium hydroxide) and thiol − 2 ml MPA (3-mercaptopropionic acid) for total serine or 1.52 g NAC (N-acetyl-L-cysteine) for D-serine determination (pH = 9.3). The volume ratio of derivatization reagent and sample was 2:1 and reaction time was 10 minutes (Vasanits et al. 2000; Kutlan et al. 2002; Kutlan et al. 2003; Molnar-Perl, 2003). Analysis: Chromatographic separation of D-serine on HPLC system type LC-10A vp (Shimadzu, Japan) has been performed in the gradient mode made of two components: (A) eluent that contained 0.21 mol/l sodium acetate adjusted to pH 5.6 with concentrated acetic acid, while (B) eluent was methanol (Zhao et al. 1995). There were three mobile phases for the analysis of total serine: (A) 0.05 mol/l acetate buffer (pH 7.3), (B) 0.1 mol/l sodium acetate – acetonitrile – methanol (46:44:10) and (C) methanol (Vasanits et al. 2000; Kutlan et al. 2002; Kutlan et al. 2003). Separations were performed on 250 × 4 mm LiChrospher RP-18e column containing 5 μm particles (Merck, Germany). Signal was detected by fluorescence detector (λem/λex 454/337 nm for D-serine, λem/λex 455/230 nm for total serine) (Zhao et al. 1995; Vasanits et al. 2000; Kutlan et al. 2002). Average of reproducibility was 4.54% for D-serine and 8.91% for total serine. Bias values were 1.58% for D-serine and 1.91% for total serine. We also determined limits of detection 0.27 μmol/l for D-serine and 2.58 μmol/l for total serine.

### Assessments

The assessments of psychopathology were performed on the same day in patients within the 4 hours period after the blood collection. The Positive and Negative Syndrome Scale (PANSS, 30 items, score 1–7) (Kay et al. 1987) and The Scale for the Assessment of Negative Symptoms (SANS, 30 items, score 0–5) (Andreasen, 1989) were employed for psychopathology assessments. The fully qualified and trained psychiatrist with experience in rating (JH) did all rating scales in patients.

### Statistical Analysis

Because of lacking normality of data distribution, non-parametric tests were used for mean comparisons. Mann-Whitney U test and Kolmogorov-Smirnov test were used for group comparisons of D-serine, total serine and D-serine/total serine ratio mean values. Correlations of variables were computed by Spearman Rank Correlation (Pair-Wise Deletion, α = 0.05). Box and scatter plots were used for graphical presentation of data (Figure 1, 2).

### Ethical Issues

All participants were thoroughly informed on its nature and requirements, and they signed the informed consent before admission to the study. The study protocol was approved by the Ethics Committee of the University Hospital Hradec Králové, Czech Republic.

### RESULTS

The values of mean serum levels of D-serine, total serine and D-serine/total serine ratio are in Table 2. The mean serum level of D-serine in patients with schizophrenia did not differ from that of healthy controls (Mann-Whitney U test, p value = .410). The mean total serine serum level was significantly lower (Kolmogorov-Smirnov test, p=.006) in comparison to the mean of healthy controls (Figure 1). D-serine/total serine ratio was in patients significantly higher (Kol-
Table 2. Amino acids serum levels: comparison of study groups.

<table>
<thead>
<tr>
<th></th>
<th>Patients (n=50)</th>
<th>Controls (n=50)</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-serine (μmol/l)</td>
<td>mean ± SD</td>
<td>3.3 ± 1.53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>median</td>
<td>2.75</td>
<td></td>
</tr>
<tr>
<td>Total serine (μmol/l)</td>
<td>mean ± SD</td>
<td>83.1 ± 27.7</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>median</td>
<td>81.4</td>
<td></td>
</tr>
<tr>
<td>D-serine ratio to total serine</td>
<td>mean ± SD</td>
<td>0.043 ± 0.023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>median</td>
<td>0.036</td>
<td>0.022</td>
</tr>
</tbody>
</table>

Commentary: * \( p < .05 \) was considered as significant; 1 Mann-Whitney \( U \) test; 2 Kolmogorov-Smirnov test.

Table 3. The results of the assessments of patients (n= 50).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean ± SD</th>
<th>Median</th>
<th>Minimum - Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>35.1 ± 11.0</td>
<td>31.5</td>
<td>21 – 62</td>
</tr>
<tr>
<td>Illness duration (years)</td>
<td>10.4 ± 10.4</td>
<td>6</td>
<td>1 – 40</td>
</tr>
<tr>
<td>Dose of medication in chlorpromazine equivalents (mg)</td>
<td>344 ± 323</td>
<td>200</td>
<td>0 – 1867</td>
</tr>
<tr>
<td>PANSS total score</td>
<td>49.1 ± 10.9</td>
<td>46.5</td>
<td>33 – 79</td>
</tr>
<tr>
<td>PANSS: P1-P7 score</td>
<td>11.1 ± 4.0</td>
<td>9</td>
<td>7 – 24</td>
</tr>
<tr>
<td>PANSS: N1-N7 score</td>
<td>14.0 ± 5.7</td>
<td>13</td>
<td>7 – 33</td>
</tr>
<tr>
<td>PANSS: G1-G16 score</td>
<td>24.1 ± 4.3</td>
<td>23</td>
<td>16 – 36</td>
</tr>
<tr>
<td>SANS total score</td>
<td>27.7 ± 18.5</td>
<td>24.5</td>
<td>0 – 80</td>
</tr>
<tr>
<td>SANS: affective flattening or blunting score</td>
<td>8.4 ± 6.0</td>
<td>8.5</td>
<td>0 – 26</td>
</tr>
<tr>
<td>SANS: alogia score</td>
<td>3.7 ± 3.9</td>
<td>3</td>
<td>0 – 16</td>
</tr>
<tr>
<td>SANS: avolition-apathy score</td>
<td>3.8 ± 3.5</td>
<td>3</td>
<td>0 – 13</td>
</tr>
<tr>
<td>SANS: anhedonia-asociality score</td>
<td>7.6 ± 6.1</td>
<td>6.5</td>
<td>0 – 22</td>
</tr>
<tr>
<td>SANS: attention score</td>
<td>4.2 ± 3.3</td>
<td>4</td>
<td>0 – 12</td>
</tr>
</tbody>
</table>

Commentary: PANSS, The Positive and Negative Syndrome Scale; SANS, The Scale for the Assessment of Negative Symptoms; P1-P7, positive symptom subscale; N1-N7, negative symptom subscale; G1-G16, general psychopathology subscale.
mogorov-Smirnov test, \( p = .022 \) than that of healthy controls (Table 2).

The mean scores of psychopathology assessments are listed in Table 3. We did not detect any association between the mean D-serine serum level and the mean scores of the total PANSS (Spearman Correlation Coefficient, \( r = 0.01, p = .93 \)) or the total SANS (\( r = -0.08, p = .58 \)). Either subscales mean scores of the PANSS or the SANS did not correlate with D-serine serum levels. The correlation coefficients are listed in Table 4.

We found statistically significant inverse correlation between the mean total serine serum level and the mean scores of the PANSS negative symptom subscale (\( r = -0.39, p = .005 \)), the total SANS (\( r = -0.44, p = .001 \)) (Figure 2), the SANS affective flattening or blunting subscale (\( r = -0.38, p = .006 \)), the SANS alogia subscale (\( r = -0.37, p = .008 \)) and the SANS anhedonia-asociality subscale (\( r = -0.52, p = .00009 \)).

Serum levels of D-serine or total serine did not relate to the age or the illness duration and chlorpromazine dose equivalent in patients (Table 4). D-serine (\( r = 0.19, p = .19 \)) or total serine (\( r = 0.10, p = .47 \)) serum levels were not associated with the age in healthy controls.

**DISCUSSION**

We did not find a significant association between serum level of D-serine and negative symptoms. In a large sample of patients, with stabilized, mostly chronic schizophrenia, whose serum levels of D-serine were analysed, we did not confirm the association of schizophrenia with decreased D-serine serum levels (Hashimoto et al. 2003; Yamada et al. 2005). On the contrary, the total serine serum levels in our patients were lower and D-serine/total serine ratio higher than in healthy controls. We found lower total serum serine levels associated with the higher intensity of negative symptoms assessed by the PANSS and the SANS. These findings has not been previously reported and may be related to the effects of the NMDA receptor agonists on negative symptoms in clinical studies (Tsai et al. 1998; Evins et al. 2002; Heresco-Levy et al. 2005; Tuominen et al. 2005).

Higher plasma concentrations of total serine and lower plasma activity of serine hydroxymethyltransferase were reported in patients with psychosis in comparison to non-psychotic patients or healthy controls (Waziri et al. 1983; Waziri et al. 1985; Wilcox et al. 1985; Waziri & Mott, 1986), and a decade later several studies confirmed the results in schizophrenia (Macciardi et al. 1990; Baruah et al. 1991; Sumiyoshi et al. 2004). However there were also reports of no difference in total serum plasma concentrations (Perry & Hansen, 1985; Carl et al. 1992; Neeman et al. 2005) and total serum CSF concentrations (Perry & Hansen, 1985) between schizophrenics and healthy controls. The only report of significantly lower total serine serum levels has been published in patients with treatment resistant schizophrenia (Tortorella et al. 2001).

Inconsistent results can be due to different populations of patients, to the influence of individual diet, the effects of antipsychotic medication or by different application of the NMDA receptor agonists in clinical studies.

---

**Table 4.** The correlations between variables and amino acids serum levels in patients (\( n = 50 \)).

<table>
<thead>
<tr>
<th>Variable</th>
<th>D-serine</th>
<th></th>
<th>Total serine</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( r )</td>
<td>( p ) value</td>
<td>( r )</td>
<td>( p ) value</td>
</tr>
<tr>
<td>Age</td>
<td>-0.07</td>
<td>.64</td>
<td>-0.20</td>
<td>.16</td>
</tr>
<tr>
<td>Illness duration</td>
<td>0.13</td>
<td>.36</td>
<td>-0.14</td>
<td>.33</td>
</tr>
<tr>
<td>Dose of medication in chlorpromazine equivalents</td>
<td>0.23</td>
<td>.10</td>
<td>0.19</td>
<td>.19</td>
</tr>
<tr>
<td>PANSS total score</td>
<td>0.01</td>
<td>.93</td>
<td>-0.22</td>
<td>.12</td>
</tr>
<tr>
<td>PANSS: P1-P7 score</td>
<td>0.08</td>
<td>.60</td>
<td>0.14</td>
<td>.34</td>
</tr>
<tr>
<td>PANSS: N1-N7 score</td>
<td>0.02</td>
<td>.89</td>
<td>-0.39</td>
<td>.005 *</td>
</tr>
<tr>
<td>PANSS: G1-G16 score</td>
<td>0.01</td>
<td>.94</td>
<td>-0.17</td>
<td>.25</td>
</tr>
<tr>
<td>SANS total score</td>
<td>-0.08</td>
<td>.58</td>
<td>-0.44</td>
<td>.001 *</td>
</tr>
<tr>
<td>SANS: affective flattening or blunting score</td>
<td>-0.003</td>
<td>.98</td>
<td>-0.38</td>
<td>.006 *</td>
</tr>
<tr>
<td>SANS: alogia score</td>
<td>-0.16</td>
<td>.27</td>
<td>-0.37</td>
<td>.008 *</td>
</tr>
<tr>
<td>SANS: avolition-apathy score</td>
<td>-0.04</td>
<td>.76</td>
<td>-0.25</td>
<td>.08</td>
</tr>
<tr>
<td>SANS: anhedonia-asociality score</td>
<td>-0.15</td>
<td>.29</td>
<td>-0.52</td>
<td>.00009 *</td>
</tr>
<tr>
<td>SANS: attention score</td>
<td>0.07</td>
<td>.65</td>
<td>-0.26</td>
<td>.07</td>
</tr>
</tbody>
</table>

Commentary: * \( p < .05 \) was considered as significant; \( r \), Spearman Correlation Coefficient; PANSS, The Positive and Negative Syndrome Scale; SANS, The Scale for the Assessment of Negative Symptoms; P1-P7, positive symptom subscale; N1-N7, negative symptom subscale; G1-G16, general psychopathology subscale.
assay techniques. Our outpatients with schizophrenia were stabilized and capable of functioning outside of the hospital. They were treated mostly with second generation antipsychotics. In contrast, higher total serine plasma levels were found in the medication-free population of mixed inpatients and outpatients (Sumiyoshi et al. 2004) or an inpatient group with a mixed medication status (Sumiyoshi et al. 2001). Hashimoto did not find differences in D-, L- or total serine serum levels between medicated or drug-naive schizophrenics (Hashimoto et al. 2003). He also didn’t find an association of D-, L- or total serine serum levels with the medication dose in chlorpromazine equivalents. On the other hand, the decrease of total serine levels after treatment with first generation antipsychotics was reported (Sumiyoshi et al. 2004).

There were concerns regarding the confounding effects of the amino acids contained in food on the amino acid serum levels in patients (Friedman, 1999). Fasting blood samples for the assays of excitatory amino acids were in some studies obtained in patients on special diet (Baruah et al. 1991; Tortorella et al. 2001). Other studies did not control for the effects of the amino acids in the food (Hashimoto et al. 2003; Neeman et al. 2005). In this study, we drew blood samples in all participants after 12 hours of overnight fasting, which should have eliminated the effect of external amino acid intake.

Additional source of different results may originate in the techniques of total serine and D-serine assays. Especially D-serine, the physiological levels of which in healthy humans are low may be sensitive to assay methods. Gas chromatography (Waziri & Mott, 1986), ion-exchange amino acid chromatography (Perry & Hansen, 1985; Neeman et al. 2005), gas chromatography–mass spectrometry (Baruah et al. 1991) or high pressure liquid chromatography (Waziri & Mott, 1986; Carl et al. 1992) were used for total serine plasma level determinations in the published clinical studies. The high-performance liquid chromatography (HPLC), that we employed to assay serum amino acids levels was used in studies with conflicting results (Tortorella et al. 2001; Hashimoto et al. 2003; Sumiyoshi et al. 2004; Yamada et al. 2005), which makes a systematic effect of the assay technique on the results unlikely. Our results correspond only with Tortorella’s report, but contradict the other findings.

It is difficult to account for the differences in findings of total serine and D-serine serum levels in patients with schizophrenia, although its practical significance appear to be considerable for the targeted treatment with the NMDA receptor agonists. Endogenous D-serine is synthesized from L-serine mainly in the cytosolic matrix of astrocytes in the brain (Schell et al. 1997). However, D-serine occurs in very low levels in blood serum, saliva and urine. It is synthesized de novo outside of the brain (Hashimoto et al. 1997) in hepatocytes, that express serine racemase (Wolosker et al. 1999), and then released into circulation. At the periphery, D-serine probably interacts with the NR1 subunit of the NMDA receptors expressed in the peripheral tissues (e.g. megakaryocytes, osteoclasts). Its metabolism by D-amino acid oxidase (DAAO) and consequent elimination takes place in the kidney cells (Schell et al. 2004). The transport through the blood-brain barrier for neutral amino acids is considered as limited (Hashimoto et al. 1997). D- and L-serine share common transport systems. The major uptake mechanism of D- and L-serine in the blood-brain barrier supplies peripherally synthesised D-serine into the brain (Yamamoto et al. 2001). The preference for a stereoselective transport of D-serine through the blood-brain barrier was reported (Bauer et al. 2005). In comparison to L-serine, D-serine from hepatocytes may have better access to the brain. We can assume, that the effects of long-term treatment on liver functions, can lead to lower peripheral synthesis of D-serine. Serum assays of endogenous D-serine may become a biomarker for its role at the NMDA receptor in the brain and eventually treatment sensitivity to exogenous excitatory amino acids in the future. However, the transport mechanisms of excitatory amino acids across the blood-brain barrier, the length and the preceding medication will have to be taken into consideration. Additional studies of excitatory amino acids in the periphery as well as in CSF may help to clarify the role of treatment related NMDA receptor dysfunction.

Acknowledgments
This study was supported by the research grant MSM 0021620816, Czech Republic.

REFERENCES

D-serine and serine in schizophrenia


